ABSTRACT The long-term effect of percutaneous and oral estrogen replacement therapy on blood pressure, plasma renin substrate, and serum estrogens was examined in a 2 year placebo-controlled study with 
ESTROGEN REPLACEMENT therapy effectively relieves menopausal subjective symptoms' and prevents osteoporosis in postmenopausal women. 2 Unopposed estrogen therapy increases the risk of endometrial cancer,3 whereas combined estrogen/gestagen therapy may eliminate this risk. 4 The metabolic side effects of estrogen therapy are influenced by the type5 and dosage6 of estrogen used and by the route of 7 administration.
Oral administration of estrogen is characterized by a considerable conversion of estradiol to estrogen8 and a first-pass liver effect with induction of the hepatic protein synthesis. 5-7 9 This alteration in liver metabolism results in changes in the serum concentration of renin substrate, clotting factors and inhibitors, and high-and low-density lipoproteins, which, respective-ly, may influence the risk of hypertension°and thromboembolic disease,7 9, 11 some of the suggested side effects of oral estrogen therapy. The change in serum lipoproteins seems, on the other hand, to be beneficial. 1 2 Percutaneous administration of estrogen avoids the first-pass liver effect and no induction of the hepatic protein synthesis seems to occur within the first 2 months of replacement therapy.7 However, in another part of the present long-term placebo-controlled study we recently demonstrated that after 6 months of treatment there was a measurable change in serum lipoproteins . 13 The aim of the present placebo-controlled study was to examine the long-term effect of 14 This method, which requires a 90 min rectilinear scanning procedure, has an accuracy of approximately 1 kg or 2.5% for LBM and that of 5% for FM measurement in a normal adult female. 4 Blood samples were taken between days 16 and 22 of the cycle, i.e., during gestagen treatment. All participants were examined in the morning after an overnight fast and tobacco abstinence, 24 hr after the last hormone dose. All serum samples were stored at -200 C until they were assayed.
Serum estrone (E,) and serum estradiol (E2) were measured by radioimmunoassays described elsewhere. '5 The intra-assay and interassay variations were, respectively, 5.6% and 10.8%
for the E, assay and 8.8% and 14% for the E2 assay.
Initially, at 1 and at 2 years, plasma renin substrate was measured in all but two subjects in the two percutaneous groups, and in a randomly selected subgroup (n= 13) from the oral E2 group. The initial clinical data from the subgroup were virtually similar to those from the oral E2 group. Renin substrate was determined by an indirect assay as the amount of angiotensin I liberated in the presence of excess renin and complete inhibition of angiotensinases. Plasma samples (25 gl, diluted 1:50) were incubated at pH 5.7 in the same mixture as that used for measurement of plasma renin activity in the presence of an excess of human renin (0. 1 Goldblatt units). The concentration of renin substrate was expressed in terms of the angiotensin I released (nanograms of angiotensin I per milliliter of plasma) assuming 1 mole of angiotensin I per mole of renin substrate. Radioimmunoassay of angiotensin I has been reported in detail. '6 Statistical analysis. For each participant the pretreatment blood pressure and body weight were assigned a value of 100% and the subsequent measurements were expressed as a percentage of this value. The cumulated response was calculated in each participant as the mean of all measurements (except to) during the 2 years of treatment. Student's t test for paired data was used to test the significance of differences within groups, and Student's t test for unpaired data was used for comparisons between two groups. One-way analysis of variance was used to compare more than two groups. E, and E2. Figure 1 shows the changes in serum estrogens during the study. In both placebo groups serum E1 and E2 remained within the postmenopausal range throughout the study. In both hormone treated groups serum E1 was significantly increased after 3 months of treatment (p < .001). In both groups, however, serum E1 continued to rise, reaching the maximum level at 6 months of therapy, after which serum E1 remained virtually constant in both groups, with a CIRCULATION higher value in the oral group than in the percutaneous group.
Results
In the percutaneous E2 group serum E2 also increased significantly after 3 months of treatment (p < .001), reaching the maximum level at 6 months and remaining constant at the same level as serum E, thereafter. In the oral E2 group the increase in serum E2 was minimal.
Blood pressure. Figure 2 shows the course of the systolic and diastolic blood pressure for each of the four groups during the study. A significant difference between the placebo and hormone group was observed only twice, both times in the diastolic blood pressure in the oral drug groups. The correlations between the diastolic and systolic blood pressure and time were insignificant in both hormone treatment groups. For both placebo groups, the correlation between diastolic blood pressure and time was significant, (r = . 162, p < .05 and r = .265, p < .001), whereas the relationship of systolic blood pressure vs time was significant only for the oral placebo group (r = .159, p < .05).
Body weight. The course of the body weight during the study is shown at the bottom of figure 2. Body weight did not change significantly in the two hormone treatment groups, but a slight significant increase (p < .01) was observed in both placebo groups. However, significant differences between the hormone treatment groups and their respective placebo groups were not observed at any time. There was no correlation between weight change and change in diastolic (r = .14, n = 1 10, NS) or systolic (r = .07, n = 1 10, NS) blood pressure (as determined with the cumulated responses during the second treatment year).
Renin substrate. Figure 3 demonstrates the changes in plasma renin substrate during the study. Initially, no significant difference between the three groups was found in plasma renin substrate. In the percutaneous E2 group, there was no significant difference from the initial value or from the placebo group at any time. In the oral drug group plasma renin substrate was significantly (p < .01) increased at 12 months of treatment, after which it remained unchanged. In the oral E2 subgroup (n = 13) we found a significant correlation (r = .66, p < .02) between the cumulated response of plasma renin substrate (mean of two examinations) and the cumulated response of E, (mean of five examinations), but no correlation between the cumulated responses of plasma renin substrate and E2 (r -.22, NS).
Discussion
The 17 and after 3 months our oral E2 group had significantly higher serum E2 than the oral placebo group for the rest of the study period (p < .001). Therefore, after 3 months of treatment the E,/E2 ratio was far above 1 in the orally treated group, whereas in the percutaneously treated group, this ratio was approximately 1 and close to that observed during the follicular phase in premenopausal women. '8 Other groups have reported similar E1/E2 ratios after 2 months of treatment.7 17The higher E,/E2 ratio after oral intake of E2 reflect the E2 oxidation, which takes place in the liver and in the intestine. 8, 19. 20 Renin substrate is a protein produced in the liver,21
and plasma renin substrate is a sensitive marker of estrogenic action on the liver.6' 7 The unchanged plasma renin substrate during percutaneous E2 administration and the increased concentration during oral estradiol treatment in the present study confirm results of short-term nonplacebo-controlled studies.7' 9 Shortterm (2 months) studies have also showed changes in lipoproteins and clotting factors after oral administration, but not after percutaneous administration, of estradiol. 7 17 In the present study, however, the serum levels of both estrogens in the percutaneous group and serum E, in the oral group continued to rise during the while others report a small but significant lowering of blood pressure and protection from hypertension27' 28 during such therapy. In the present study we found no change in systolic blood pressure and a tendency toward a lowering of diastolic blood pressure during both percutaneous and oral estradiol therapy. Exactly the same response has been reported during oral estrogen replacement therapy with higher estradiol doses.27 The blood pressure response in the present study could have been due to changes in body weight, but significant differences in body weight between the hormone groups and their placebo groups were not observed at any time. Furthermore, changes in blood pressure did not correlate with changes in body weight in the present study.
The increase in plasma renin substrate observed in the oral E2 group might, theoretically, cause development of hypertension.'0 However, no significant correlation was found between plasma renin substrate and systolic or diastolic blood pressure in any of the groups, and none of the subjects developed hypertension over the 2 year period. However, some women may be hypersensitive to renin substrate and therefore develop hypertension.
Oral administration of micronized progesterone exerts little of no adverse effect on lipid metabolism'3 and it does not influence bone or calcium metabolism.29
In the present study, none of the measured variables (El, E2, renin substrate, diastolic or systolic blood pressure) appeared to be influenced by the addition of progesterone.
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